➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Medtronic
Colorcon
Moodys
Dow

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EDARAVONE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Edaravone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00153946 ↗ Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Japan Cardiovascular Research Foundation Phase 4 2004-08-01 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00153946 ↗ Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Combination Therapy for Acute Ischemic Stroke Study Group Phase 4 2004-08-01 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00200356 ↗ Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke Completed Mitsubishi Tanabe Pharma Corporation Phase 4 2004-08-01 This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
NCT00265239 ↗ Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Japan Heart Foundation Phase 4 2001-04-01 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
NCT00265239 ↗ Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Kumamoto University Phase 4 2001-04-01 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
NCT00330681 ↗ Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Completed Mitsubishi Tanabe Pharma Corporation Phase 3 2006-05-01 The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Edaravone

Condition Name

Condition Name for Edaravone
Intervention Trials
Healthy Adult Subjects 6
ALS 5
Amyotrophic Lateral Sclerosis 4
Acute Ischemic Stroke 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Edaravone
Intervention Trials
Motor Neuron Disease 12
Amyotrophic Lateral Sclerosis 12
Stroke 10
Ischemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Edaravone

Trials by Country

Trials by Country for Edaravone
Location Trials
China 41
Japan 12
United States 2
Canada 1
Hungary 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Edaravone
Location Trials
Kansas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Edaravone

Clinical Trial Phase

Clinical Trial Phase for Edaravone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 8
Phase 2 13
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Edaravone
Clinical Trial Phase Trials
Not yet recruiting 15
Completed 14
Recruiting 10
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Edaravone

Sponsor Name

Sponsor Name for Edaravone
Sponsor Trials
Mitsubishi Tanabe Pharma Corporation 15
Jiangsu Simcere Pharmaceutical Co., Ltd. 3
Mitsubishi Tanabe Pharma Development America, Inc. 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Edaravone
Sponsor Trials
Other 30
Industry 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Colorcon
AstraZeneca
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.